Home
/

What is a Total Cholesterol Blood Test?

REVIEWED BY
Bill Maish, MD
Clinical Content Consultant
Published
May 30, 2026
Last updated
May 30, 2026
Quick answer:

Total cholesterol measures the sum of cholesterol in all lipoproteins (LDL, HDL, VLDL, remnants); desirable values are below 200 mg/dL, borderline 200–239, and high at 240 or above. This waxy sterol is associated with cell membrane structure, hormone synthesis, and bile acid production, but interpretation improves when viewed alongside a full lipid panel and clinical context.

Read more →
Table of contents

The Sum of Cholesterol Across Every Lipoprotein Carrier

Total cholesterol blood testing measures the overall amount of cholesterol circulating in your blood. Cholesterol is a waxy, fat-like molecule (sterol lipid) that your body makes mainly in the liver and also absorbs from animal-based foods. Because cholesterol does not dissolve in water, it travels through the bloodstream packaged inside carrier particles called lipoproteins. A total cholesterol result adds up the cholesterol carried by all major lipoprotein classes, including LDL, HDL, and others (VLDL remnants).

Cholesterol is essential for life. It is a key structural component of cell membranes, helping cells maintain proper shape and function (membrane fluidity). It is also the raw material for steroid hormones, bile acids that help digest fats, and vitamin D (steroidogenesis and bile acid synthesis). A total cholesterol measurement reflects the size of the circulating cholesterol pool and the amount being shuttled among tissues by lipoproteins at a given moment. It provides a snapshot of the body's supply and transport of this vital molecule, which is continually produced, used, recycled, and cleared by the liver and other tissues.

A Whole-Body Snapshot of Cardiometabolic Balance

Total cholesterol is the sum of cholesterol carried by LDL, HDL, and other lipoproteins. It tracks how your body packages a vital building block for cell membranes, hormones, and bile acids—and whether those particles are moving cholesterol safely or depositing it in artery walls. Because every organ depends on membrane integrity and blood flow, this number provides a whole‑body snapshot of cardiometabolic balance.

Big picture: total cholesterol is a screening lens, best interpreted with LDL/non‑HDL or apoB, triglycerides, glucose/insulin status, thyroid and liver function, blood pressure, and family history. Its long‑term relevance is cardiovascular risk—heart attack, stroke, and impaired organ perfusion across the body.

Desirable, Borderline, High — and What Sits Behind the Number

Typical desirable values are below 200, borderline 200–239, and high at 240 or more. For most people, better outcomes sit toward the lower end of normal, though interpretation improves when viewed alongside LDL, non‑HDL, HDL, and triglycerides. For cardiovascular risk, within reference ranges generally sits toward the lower half of the lab range when HDL and triglycerides are healthy.

Unusually low total cholesterol can reflect low production (advanced liver disease, hyperthyroidism), poor intake or absorption of fats, chronic illness, or rare genetic conditions. When driven by fat malabsorption, it may travel with fat‑soluble vitamin deficits (A, D, E, K), showing up as night‑vision changes, neuropathy or balance issues, bone fragility, or easy bruising. In children, very low values can accompany growth or nutrient‑absorption problems. During pregnancy, cholesterol normally rises; unexpectedly low values may signal maternal undernutrition or illness and warrant context‑specific interpretation. Systemically, lows can coincide with poor transport of fat‑soluble vitamins and inflammatory states.

Being in range suggests enough cholesterol for membranes and hormone synthesis without excessive atherogenic burden.

Higher totals usually indicate excess LDL and remnant particles that infiltrate arteries, fueling atherosclerosis. Symptoms are uncommon until vascular disease appears—chest pain, transient neurologic events, leg cramps with walking; visible clues can include tendon xanthomas or corneal arcus. Men tend to manifest vascular disease earlier; risk in women climbs after menopause. Markedly high levels in children or teens suggest familial hypercholesterolemia. High values usually reflect more apoB‑containing particles (LDL/VLDL) from genetics, insulin resistance, too little thyroid hormone (hypothyroidism), nephrotic syndrome, or cholestatic liver disease. Levels rise with age, after menopause, and during pregnancy. A high total driven by very high HDL is less informative.

What Can Shift a Total Cholesterol Reading

Notes: Non‑fasting is acceptable. Acute illness can transiently lower totals. Many medicines shift values—statins lower; retinoids and some diuretics can raise—so interpret with LDL, non‑HDL, HDL, triglycerides, and apoB when available.

FAQs

Cholesterol, Total testing measures the total amount of cholesterol carried by all lipoproteins in your blood to provide a high-level view of cholesterol burden and cardiovascular risk context.

Testing shows where your cholesterol burden sits now, how it changes over time, and whether more detailed lipid measurements are warranted.

Frequency depends on personal risk factors, life stage, and tracking goals. Many people retest periodically to monitor trends and responses to changes.

Dietary pattern, physical activity, weight changes, alcohol use, medications, thyroid function, kidney and liver health, genetics, pregnancy, menopause, and aging can all influence results.

Follow the instructions provided with your test. Some lipid panels specify fasting; if combined with other labs, preparation requirements may vary.

Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.

We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.

References

  1. Prospective Studies Collaboration. (2007). Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet, 370(9602), 1829-1839. https://doi.org/10.1016/S0140-6736(07)61778-4
  2. Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., Goldberg, R., Heidenreich, P. A., Hlatky, M. A., Jones, D. W., Lloyd-Jones, D., Lopez-Pajares, N., Ndumele, C. E., Orringer, C. E., Peralta, C. A., ... Yeboah, J. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation, 139(25), e1082-e1143. https://doi.org/10.1161/CIR.0000000000000625
  3. Emerging Risk Factors Collaboration. (2009). Major lipids, apolipoproteins, and risk of vascular disease. JAMA, 302(18), 1993-2000. https://doi.org/10.1001/jama.2009.1619
  4. Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., Graham, I. M., Halliday, A., Landmesser, U., Mihaylova, B., Pedersen, T. R., Riccardi, G., Richter, D. J., Sabatine, M. S., Taskinen, M. R., ... Wiklund, O. (2020). 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. European Heart Journal, 41(1), 111-188. https://doi.org/10.1093/eurheartj/ehz455
  5. Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., Watts, G. F., Borén, J., Fazio, S., Horton, J. D., Masana, L., Nicholls, S. J., Nordestgaard, B. G., van de Sluis, B., Taskinen, M. R., ... Catapano, A. L. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 38(32), 2459-2472. https://doi.org/10.1093/eurheartj/ehx144

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey